Drugs for Oropharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 150)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Mitomycin |
Approved |
Phase 4 |
|
50-07-7 |
5746 |
Synonyms:
7-Amino-9alpha-methoxymitosane
7-Amino-9a-methoxymitosane
7-Amino-9α-methoxymitosane
Ametycine
Mitamycin
Mitocin C
MitocinC
Mitocin-C
Mitomycin
|
Mitomycin C
Mitomycin-C
MITOSOL
MITOZYTREX
MMC
Muamycin
Mutamycin
MYTOZYTREX
NSC-26980
|
|
2 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
3 |
|
Fluorouracil |
Approved |
Phase 3 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
4 |
|
Gabapentin |
Approved, Investigational |
Phase 3 |
|
60142-96-3 |
3446 |
Synonyms:
1-(Aminomethyl)cyclohexaneacetate
1-(Aminomethyl)cyclohexaneacetic acid
2-[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
Aclonium
Apo gabapentin
Apo-gabapentin
ApoGabapentin
CI 945
CI 945|Go 3450|GOE 2450|GOE 3450|Neurontin®
CI-945
Convalis
DM-1796
GABAPENTIN
GABAPENTIN GR
Gabapentin hexal
Gabapentin ratiopharm
Gabapentin stada
Gabapentina
Gabapentine
|
Gabapentine [INN-French]
Gabapentino
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentin-ratiopharm
Gabapentinum
Gabapentinum [INN-Latin]
Gabapetin
GO 3450
GOE 2450
GOE 3450
GOE-3450
Gralise
Neurontin
Novo gabapentin
Novo-gabapentin
NovoGabapentin
Novo-gabapentine
PMS-Gabapentin
|
|
5 |
|
Clonidine |
Approved |
Phase 2, Phase 3 |
|
4205-91-8, 4205-90-7 |
2803 20179 |
Synonyms:
2-((2,6-Dichlorophenyl)imino)imidazolidine
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
2-[(2,6-Dichlorophenyl)imino]imidazoline
Adesipress
Boehringer ingelheim brand OF clonidine hydrochloride
Catapres
CATAPRES P.L.
CATAPRES TTS 1
CATAPRES TTS 2
CATAPRES TTS 3
Catapres®|Kapvay®
Catapresan
Catapressan
Catapres-TTS
CATAPRES-TTS-1
CATAPRES-TTS-2
CATAPRES-TTS-3
Catarpres
Catarpresan
Catarpres-TTS
Chlofazoline
Chlophazolin
Chlornidinum
Clofelin
Clofenil
Clonidin
Clonidina
Clonidine
Clonidine dihydrochloride
CLONIDINE HCL
Clonidine hydrochloride
|
Clonidine monohydrobromide
Clonidine monohydrochloride
Clonidinhydrochlorid
Clonidinum
Clonidinum [INN-Latin]
Clonistada
Clopheline
CLORPRES
COMBIPRES
DICHLORANILINO IMIDAZOLIN
Dihydrochloride, clonidine
Dixarit
DURACLON
Duraclont
Gemiton
Hemiton
Hydrochloride, clonidine
Ipotensium
Isoglaucon
JENLOGA
KAPVAY
KAPVAY®
Klofelin
Klofenil
Monohydrobromide, clonidine
Monohydrochloride, clonidine
ST 155BS
ST-155
ST-155BS
ST-155-BS
Tenso-Timelets
|
|
6 |
|
Atezolizumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
7 |
|
Sucralfate |
Approved |
Phase 3 |
|
54182-58-0 |
|
Synonyms:
ANTEPSIN
CARAFATE
Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum
Octaaluminium(3+) ion (2R,3S,4S,5R)-2,4-bis(sulfonatooxy)-5-[(sulfonatooxy)methyl]-5-{[(2S,3R,4S,5R,6R)-3,4,5-tris(sulfonatooxy)-6-[(sulfonatooxy)methyl]oxan-2-yl]oxy}oxolan-3-yl sulfuric acid hexadecahydroxide
Octaaluminium(3+) ion (2R,3S,4S,5R)-2,4-bis(sulphonatooxy)-5-[(sulphonatooxy)methyl]-5-{[(2S,3R,4S,5R,6R)-3,4,5-tris(sulphonatooxy)-6-[(sulphonatooxy)methyl]oxan-2-yl]oxy}oxolan-3-yl sulphate hexadecahydroxide
Octaaluminium(3+) ion (2R,3S,4S,5R)-2,4-bis(sulphonatooxy)-5-[(sulphonatooxy)methyl]-5-{[(2S,3R,4S,5R,6R)-3,4,5-tris(sulphonatooxy)-6-[(sulphonatooxy)methyl]oxan-2-yl]oxy}oxolan-3-yl sulphuric acid hexadecahydroxide
Sucralfat
|
Sucralfate
SUCRALFATE HYDRATE
Sucralfato
Sucralfatum
Sucralfic acid
ULCERLMIN
|
|
8 |
|
Bevacizumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
9 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
10 |
|
Dexamethasone acetate |
Approved, Investigational, Vet_approved |
Phase 3 |
|
1177-87-3 |
3680 |
Synonyms:
16alpha-Methyl-9alpha-fluoroprednisolone 21-acetate
2-{1-fluoro-14,17-dihydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethyl acetic acid
9alpha-Fluoro-16alpha-methylprednisolone acetate
DECADRON-LA
Dexamethasone 21-acetate
|
DEXAMETHASONE ACETATE
Dexamethasone acetate anhydrous
Dexamethasone acetate, anhydrous
Dexamethasone acetic acid
Dexamethasoni acetas
|
|
11 |
|
Dexamethasone |
Approved, Investigational, Vet_approved |
Phase 3 |
|
50-02-2 |
3003 5743 |
Synonyms:
[<sup>3</sup>H]-dexamethasone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16a-Methyl-9a-fluoro-1-dehydrocortisol
16Α-methyl-9α-fluoro-1-dehydrocortisol
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16a-methyl-9a-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
9a-Fluoro-16a-methylprednisolone
9a-Fluoro-16BETA-methylprednisolone
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-Fluoro-16alpha-methyl-prednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9Α-fluoro-16α-methylprednisolone
Adexone
Aeroseb-D
Aeroseb-dex
Ak dex OPH otic soln 0.1%
Alcon brand OF dexamethasone
alpha -Fluoro-16-alpha -methylcortisol
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (veterinary)
Bisu DS
Calonat
Corson
Corsone
Cortisumman
DALALONE
Decacort
Decacortin
Decaderm
Decadron
Decadron Tablets, Elixir
Decadron®|desametasone|fluormethylprednisolone
DECADRON-75
DECADRON-LA
Decagel
Decaject
Decaject l.a.
Decaject-l.a.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
DEX
DEXA
Dexa mamallet
DEXACEN-4
Dexacidin
Dexacort
Dexacortal
Dexa-cortidelt
Dexacortin
Dexa-cortisyl
DEXACORTISYL
Dexadeltone
Dexafarma
DEXAFREE
DEXAIR
Dexalona
Dexaltin
Dexa-Mamallet
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
DEXAMETHASONE
Dexaméthasone
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
DEXAMETHASONE METASULFOBENZOATE SODIUM
DEXAMETHASONE PALMITATE
Dexamethasone sodium phosphate
|
DEXAMETHASONE VALERATE
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexa-scheroson
Dexa-sine
Dexason
Dexasone
Dexasone 0.5MG
Dexasone 0.75MG
Dexasone 4MG
Dexasporin
Dex-ide
Dexinolon
Dexinoral
Dexone
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
Dexonium
Dexpak
DEXSOL
Dextelan
DEXTENZA
DEXYCU KIT
Dezone
Dinormon
DROPODEX
DXM
DXM833
DXMS
ECR brand OF dexamethasone
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy brand OF dexamethasone
Gammacorten
GPPE EAR SPY
Hexadecadrol
Hexadrol
Hexadrol elixir
Hexadrol Tablets
HL-Dex
ICN brand OF dexamethasone
IontoDex
Isopto-dex
ISV-305
KORTICO INJECTION
Lokalison F
Loverine
Luxazone
MARTAPAN
Maxidex
Maxidex ont 0.1%
Maxidex sus 0.1%
Maxitrol
Mediamethasone
Merck brand OF dexamethasone
Merz brand 1 OF dexamethasone
Merz brand 2 OF dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
Mymethasone
Naquasone (veterinary)
NEODECADRON
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
NSC 34521
NSC-34521
Ocu-trol
Oradexon
OTO-104
OTOMIZE
OZURDEX
Pet derm III
Pet-Derm Iii
PHL-Dexamethasone
PMS Dexamethasone elixir 0.5mg/5ML
PMS-Dexamethasone
Policort
Posurdex
Prednisolon F
Prednisolone F
Prodex
Sandoz dexamethasone
SK-Dexamethasone
SOFRADEX
SPERSADEX COMP
Spoloven
Sunia sol D
Superprednol
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
Visumetazone
|
|
12 |
|
Durvalumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
1428935-60-7 |
|
Synonyms:
|
13 |
|
Cetuximab |
Approved |
Phase 3 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
14 |
|
Docetaxel |
Approved, Investigational |
Phase 3 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
15 |
|
Kava |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
9000-38-8 |
|
16 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
17 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
18 |
|
Anti-Anxiety Agents |
|
Phase 3 |
|
|
|
19 |
|
Excitatory Amino Acid Antagonists |
|
Phase 3 |
|
|
|
20 |
|
Psychotropic Drugs |
|
Phase 3 |
|
|
|
21 |
|
Anticonvulsants |
|
Phase 3 |
|
|
|
22 |
|
Neurotransmitter Agents |
|
Phase 2, Phase 3 |
|
|
|
23 |
|
Anti-Ulcer Agents |
|
Phase 3 |
|
|
|
24 |
|
Antacids |
|
Phase 3 |
|
|
|
25 |
|
Gastrointestinal Agents |
|
Phase 3 |
|
|
|
26 |
|
Mitogens |
|
Phase 2, Phase 3 |
|
|
|
27 |
|
Adrenergic alpha-Agonists |
|
Phase 2, Phase 3 |
|
|
|
28 |
|
Adrenergic Agonists |
|
Phase 2, Phase 3 |
|
|
|
29 |
|
Adrenergic Agents |
|
Phase 2, Phase 3 |
|
|
|
30 |
|
Antihypertensive Agents |
|
Phase 2, Phase 3 |
|
|
|
31 |
|
Analgesics |
|
Phase 2, Phase 3 |
|
|
|
32 |
|
Sympatholytics |
|
Phase 2, Phase 3 |
|
|
|
33 |
|
Aloe |
|
Phase 3 |
|
|
|
34 |
|
Angiogenesis Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
35 |
|
Endothelial Growth Factors |
|
Phase 2, Phase 3 |
|
|
|
36 |
|
Immunologic Factors |
|
Phase 2, Phase 3 |
|
|
|
37 |
|
Antineoplastic Agents, Hormonal |
|
Phase 3 |
|
|
|
38 |
|
Hormones |
|
Phase 3 |
|
|
|
39 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
40 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
41 |
|
Antiemetics |
|
Phase 3 |
|
|
|
42 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
43 |
|
glucocorticoids |
|
Phase 3 |
|
|
|
44 |
|
Anti-Inflammatory Agents |
|
Phase 3 |
|
|
|
45 |
|
Antineoplastic Agents, Immunological |
|
Phase 2, Phase 3 |
|
|
|
46 |
|
Immunoglobulins |
|
Phase 2, Phase 3 |
|
|
|
47 |
|
Antibodies |
|
Phase 2, Phase 3 |
|
|
|
48 |
|
Antibodies, Monoclonal |
|
Phase 2, Phase 3 |
|
|
|
49 |
|
HIV Protease Inhibitors |
|
Phase 3 |
|
|
|
50 |
|
BB 1101 |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 223)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer |
Active, not recruiting |
NCT03691441 |
Phase 4 |
Chemotherapy |
2 |
Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer |
Completed |
NCT01434394 |
Phase 2, Phase 3 |
Neo-adjuvant Erbitux-based chemotherapy |
3 |
Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) |
Completed |
NCT00964977 |
Phase 3 |
|
4 |
Phase III Trial Testing the Benefit of Intensity-modulated Radiotherapy With Weekly Replanifications Versus Intensity Modulated Radiotherapy With Only One Planification in Locally Advanced Oropharynx Carcinoma for Decreasing Xerostomia |
Completed |
NCT01874587 |
Phase 3 |
|
5 |
Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma |
Completed |
NCT00158652 |
Phase 3 |
5FU, Paraplatin |
6 |
Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma |
Completed |
NCT00158678 |
Phase 3 |
concomitant cisplatin |
7 |
A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma |
Completed |
NCT00162708 |
Phase 2, Phase 3 |
CDDP, 5 Fu |
8 |
Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma |
Completed |
NCT03269344 |
Phase 3 |
Gabapentin;Placebo Oral Capsule |
9 |
Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx |
Completed |
NCT00003627 |
Phase 3 |
cisplatin;fluorouracil |
10 |
Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck |
Recruiting |
NCT01893307 |
Phase 2, Phase 3 |
|
11 |
A Phase 2b/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-induced Severe Oral Mucositis in Patients With Oropharyngeal Cancer |
Recruiting |
NCT04648020 |
Phase 2, Phase 3 |
Clonidine HCl Mucoadhesive Buccal Tablet;Placebo Mucoadhesive Buccal Tablet |
12 |
Phase III Randomised Controlled Trial Comparing Alternative Regimens for Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer |
Recruiting |
NCT04116047 |
Phase 3 |
Cisplatin;Durvalumab |
13 |
Patient Reported Outcomes in Term of Swallowing and Quality of Life After Prophylactic Versus Reactive Percutaneous Endoscopic Gastrostomy Tube Placement in Advanced Oropharyngeal Cancer Patients Treated With Definitive Chemo-radiotherapy |
Recruiting |
NCT04019548 |
Phase 3 |
Cisplatin injection |
14 |
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer |
Recruiting |
NCT03952585 |
Phase 2, Phase 3 |
Cisplatin |
15 |
A Phase III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer |
Recruiting |
NCT02215265 |
Phase 3 |
Cisplatin |
16 |
Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis: a Single-blind Randomized Controlled Trial |
Recruiting |
NCT05369234 |
Phase 3 |
Carafate |
17 |
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC |
Recruiting |
NCT03811015 |
Phase 2, Phase 3 |
Cisplatin |
18 |
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers |
Recruiting |
NCT05063552 |
Phase 2, Phase 3 |
Carboplatin;Cisplatin;Docetaxel |
19 |
An Investigation of Postoperative Pain, Why Still in Hospital and Days Alive and Out of Hospital Following Transoral Robotic Surgery for Squamous Cell Carcinoma of Unknown Primary and Obstructive Sleep Apnea |
Active, not recruiting |
NCT04189107 |
Phase 3 |
Dexamethasone;Placebo |
20 |
The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer |
Active, not recruiting |
NCT01706939 |
Phase 3 |
Carboplatin |
21 |
Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer |
Active, not recruiting |
NCT01302834 |
Phase 3 |
cisplatin |
22 |
DART-HPV: A Phase III Evaluation of De-escalated Adjuvant Radiation Therapy for HPV-Associated Oropharynx Cancer |
Active, not recruiting |
NCT02908477 |
Phase 3 |
Docetaxel;Cisplatin |
23 |
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin |
Active, not recruiting |
NCT03258554 |
Phase 2, Phase 3 |
|
24 |
Primary Surgery Vs Primary Chemoradiation for Oropharyngeal Cancer (Scope Trial) - A Phase II/III Integrated Design Randomized Control Trial |
Not yet recruiting |
NCT05144100 |
Phase 2, Phase 3 |
Cisplatin based chemotherpay |
25 |
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer. A Phase III Randomized Controlled Trial |
Not yet recruiting |
NCT05451004 |
Phase 3 |
|
26 |
Evaluation of OraTest in Combination With Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer: Phase III Clinical Trial Comparing the Sensitivity and Assessing the Specificity of OraTest in Combination With Visual Examination and Visual Examination Alone in Patients at High Risk as Defined by Age and Lifestyle Factors (ZIL-401) |
Terminated |
NCT00537199 |
Phase 3 |
OraTest |
27 |
Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer |
Terminated |
NCT01066741 |
Phase 3 |
Homeodent®;1.4% Sodium Bicarbonate solution |
28 |
Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer |
Unknown status |
NCT02960724 |
Phase 2 |
|
29 |
Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx |
Unknown status |
NCT01516996 |
Phase 2 |
docetaxel and cisplatin |
30 |
Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer |
Unknown status |
NCT01932697 |
Phase 2 |
Docetaxel |
31 |
Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] |
Completed |
NCT00064103 |
Phase 1, Phase 2 |
|
32 |
Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer |
Completed |
NCT00006360 |
Phase 1, Phase 2 |
radioprotection |
33 |
Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer |
Completed |
NCT01032928 |
Phase 2 |
|
34 |
Phase II Trial of Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer |
Completed |
NCT03258008 |
Phase 2 |
Utomilumab |
35 |
Neo-adjuvant Erbitux-based Chemotherapy Followed by Surgery and Radiotherapy for Locally Advanced Oral/Oropharyngeal Cancer |
Completed |
NCT01440270 |
Phase 2 |
Neo-adjuvant Erbitux-based chemotherapy |
36 |
A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer |
Completed |
NCT02159703 |
Phase 2 |
|
37 |
A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers |
Completed |
NCT02280811 |
Phase 1, Phase 2 |
Fludarabine;Cyclophosphamide;Aldesleukin |
38 |
Physiotherapy Versus no Physiotherapy to Patients Suffering From Head and Neck Cancer Undergoing Radiotherapy Treatment |
Completed |
NCT00780312 |
Phase 2 |
|
39 |
Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma |
Completed |
NCT01695122 |
Phase 2 |
Valproic Acid |
40 |
Evaluation of Photobiomodumation Using LED Lamp as a Curative Treatment for Oral or Oropharyngeal Mucositic Inducted by Radiation Therapy |
Completed |
NCT04251949 |
Phase 2 |
|
41 |
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
Completed |
NCT03422536 |
Phase 2 |
Ficlatuzumab |
42 |
Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial |
Completed |
NCT00330382 |
Phase 2 |
Bowman-Birk inhibitor concentrate |
43 |
Randomised Pilot Study of Therabite® Versus Wooden Spatula in the Amelioration of Trismus in Head and Neck Cancer Patients. (Trismus Trial) |
Completed |
NCT01733797 |
Phase 2 |
|
44 |
A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers |
Completed |
NCT01585428 |
Phase 2 |
Fludarabine;Cyclophosphamide;Aldesleukin |
45 |
Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis |
Completed |
NCT01806675 |
Phase 1, Phase 2 |
18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2 |
46 |
Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer |
Completed |
NCT01469429 |
Phase 1, Phase 2 |
chemoprevention |
47 |
A Phase II, Randomized, Open-Label, Single Center Study In Patients With Advanced Head And Neck Cancer To Investigate Efficacy And Safety Of Standard Chemoradiation And Add-On Concurrent Cetuximab ± Consolidation Cetuximab |
Completed |
NCT01435252 |
Phase 2 |
Cetuximab |
48 |
Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study. |
Completed |
NCT01173692 |
Phase 2 |
Minocycline;Placebo |
49 |
A Prospective Non-Inferiority Trial of the Use of Adaptive Radiotherapy for Head and Neck Cancer Undergoing Radiation Therapy |
Completed |
NCT03096808 |
Phase 2 |
|
50 |
Phase I/II Study of Split-dose TPF-Induction Chemotherapy Before Surgery of Oropharyngeal and Cavity of the Mouth Cancer |
Completed |
NCT01108042 |
Phase 1, Phase 2 |
Taxotere, Cisplatin, 5-Fluorouracil (5-FU) |
|